WallStSmart

Vivani Medical Inc. (VANI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Vivani Medical Inc. stock (VANI) is currently trading at $1.13. Analyst consensus price target for VANI is $5.00. WallStSmart rates VANI as Sell.

  • VANI PE ratio analysis and historical PE chart
  • VANI PS ratio (Price-to-Sales) history and trend
  • VANI intrinsic value — DCF, Graham Number, EPV models
  • VANI stock price prediction 2025 2026 2027 2028 2029 2030
  • VANI fair value vs current price
  • VANI insider transactions and insider buying
  • Is VANI undervalued or overvalued?
  • Vivani Medical Inc. financial analysis — revenue, earnings, cash flow
  • VANI Piotroski F-Score and Altman Z-Score
  • VANI analyst price target and Smart Rating
VANI

Vivani Medical Inc.

NASDAQHEALTHCARE
$1.13
$0.01 (0.89%)
52W$0.91
$1.92
Target$5.00+342.5%

📊 No data available

Try selecting a different time range

WallStSmart

Smart Analysis

Vivani Medical Inc. (VANI) · 4 metrics scored

Smart Score

6
out of 100
Grade: F
Avoid
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.

Vivani Medical Inc. (VANI) Key Strengths (0)

Avg Score: 0/10

Supporting Valuation Data

VANI Target Price
$5
292% Upside

Vivani Medical Inc. (VANI) Areas to Watch (4)

Avg Score: 1.8/10
Return on EquityProfitability
-265.00%0/10

Company is destroying shareholder value

Price/BookValuation
70.102/10

Very expensive at 70.1x book value

Institutional Own.Quality
6.72%2/10

Very low institutional interest at 6.72%

Market CapQuality
$91M3/10

Micro-cap company with very limited liquidity and high volatility

Vivani Medical Inc. (VANI) Detailed Analysis Report

Overall Assessment

This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

Limited fundamental strengths were identified. The bull case requires improvement in core metrics.

The Bear Case

The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (70.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -265.00%.

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -265.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.

Risk Considerations

Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

VANI Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

Compare VANI with Competitors

Top BIOTECHNOLOGY stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Vivani Medical Inc. (VANI) · HEALTHCAREBIOTECHNOLOGY

The Big Picture

Vivani Medical Inc. operates as a stable business with moderate growth and solid fundamentals.

Key Findings

Negative Free Cash Flow

Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.

What to Watch Next

Volatility is elevated with a beta of 3.36, so expect amplified moves relative to the broader market.

Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vivani Medical Inc..

Bottom Line

Vivani Medical Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions(10 last 3 months)

Total Buys
10
Total Sells
0
Jan 27, 2026(1 transaction)
WILLIAMS, GREGG
Director, 10% Owner
Buy
Shares
+1,351,351
Dec 29, 2025(1 transaction)
MENDELSOHN, AARON
Director
Buy
Shares
+20,000

Data sourced from SEC Form 4 filings

Last updated: 11:30:25 AM

About Vivani Medical Inc.(VANI)

Exchange

NASDAQ

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Country

USA

Vivani Medical Inc. (VANI) is an innovative biotechnology firm committed to transforming the management of chronic diseases through its proprietary drug delivery systems. The company specializes in biocompatible implants that facilitate sustained medication release, addressing significant health challenges, particularly in diabetes and neurological conditions. With a robust product pipeline and a strong intellectual property portfolio, Vivani is poised to meet critical unmet medical needs, making it an attractive prospect for institutional investors seeking exposure in the rapidly evolving healthcare sector.